Clinical Trial Update: A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration [Phase 1, Phase 2]

View source ↗

Summary

Status update for a Phase 1/2 trial evaluating dabrafenib, trametinib, and hydroxychloroquine in patients with recurrent low-grade or high-grade gliomas harbori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma
• Low-grade Glioma
• Neurofibromatosis Type 1-associated Glioma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Hydroxychloroquine (hydroxychloroquine)
• Trametinib (trametinib)

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING